To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic characteristics, multiple ascending doses of SYHA1805 tablets or matching placebo tablets will be randomly administered to 36 Chinese healthy subjects under fasting condition.
This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-dose of SYHA1805.